GAITHERSBURG, Md., Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42th Annual J.P. Morgan Healthcare Conference.
Conference Details: | |||||
Presentation and Q&A | |||||
Date: | Monday, January 8, 2024 | ||||
Time: | 5:15 – 5:55 p.m. Pacific Standard Time (PST) | ||||
Location: | Westin St. Francis Hotel in San Francisco, California | ||||
Moderator: | Eric Joseph, Ph.D., Executive Director, Biotechnology Equity Research | ||||
Novavax participants: | John C. Jacobs, President and Chief Executive Officer | ||||
Conference | |||||
Event: | Investor Meetings | ||||
Date: | Monday, January 8, 2024 | ||||
Recordings
A replay of the recorded presentation and Q&A will be available through the Events & presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Ali Chartan
240-720-7804
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.40 |
| Daily Change: | -0.15 -1.99 |
| Daily Volume: | 3,814,881 |
| Market Cap: | US$1.200B |
May 19, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
